Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...
The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...
WATE Knoxville on MSN7h
How to combat seasonal affective disorder as it gets darker earlierThe days are getting shorter as we "fall back” into standard time and it may be affecting your mood. While we settle into our ...
Cybin launches Phase 3 trials for CYB003, aiming to offer lasting relief for Major Depressive Disorder. Backed by promising ...
Efforts have been made in recent years to clarify the value of exercise as an adjunctive or independent treatment for major ...
Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.
Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can ...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...
The firm expects to report its 12-month phase 2 data next week, with topline results from a phase 3 trial anticipated in 2026 ...
de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback